MXPA05009251A - Composiciones y metodos para diagnosticar y tratar asma u otras enfermedades alergicas o inflamatorias. - Google Patents

Composiciones y metodos para diagnosticar y tratar asma u otras enfermedades alergicas o inflamatorias.

Info

Publication number
MXPA05009251A
MXPA05009251A MXPA05009251A MXPA05009251A MXPA05009251A MX PA05009251 A MXPA05009251 A MX PA05009251A MX PA05009251 A MXPA05009251 A MX PA05009251A MX PA05009251 A MXPA05009251 A MX PA05009251A MX PA05009251 A MXPA05009251 A MX PA05009251A
Authority
MX
Mexico
Prior art keywords
component
allergic
inflammatory diseases
methods
expression
Prior art date
Application number
MXPA05009251A
Other languages
English (en)
Inventor
Chen Heng
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA05009251A publication Critical patent/MXPA05009251A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001—Arginase (3.5.3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD

Abstract

La presente invencion proporciona las composiciones y metodos utiles para detectar o tratar el asma u otras enfermedades alergicas o inflamatorias. En un aspecto, los metodos de la presente invencion incluyen la inhibicion de la actividad o expresion de un componente de una via metabolica de la arginina en tejidos afectados por el asma u otras enfermedades alergicas o inflamatorias. En muchas modalidades, el componente que es inhibido es un transportador de aminoacido cationico, una arginasa o un componente corriente abajo de la via de la arginasa. En muchas otras modalidades, la actividad o expresion del componente es inhibida por un agente que se enlaza al componente. En otras muchas modalidades, la actividad o expresion del componente es inhibida por un agente que se enlaza a un polinucleotido que codifica para el componente.
MXPA05009251A 2003-03-04 2004-03-04 Composiciones y metodos para diagnosticar y tratar asma u otras enfermedades alergicas o inflamatorias. MXPA05009251A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45139603P 2003-03-04 2003-03-04
US47587003P 2003-06-05 2003-06-05
PCT/US2004/006470 WO2005003164A2 (en) 2003-03-04 2004-03-04 Compositions and methods for diagnosing and treating asthma or other allergic or inflammatory diseases

Publications (1)

Publication Number Publication Date
MXPA05009251A true MXPA05009251A (es) 2005-10-19

Family

ID=33567303

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009251A MXPA05009251A (es) 2003-03-04 2004-03-04 Composiciones y metodos para diagnosticar y tratar asma u otras enfermedades alergicas o inflamatorias.

Country Status (11)

Country Link
US (2) US20040234517A1 (es)
EP (1) EP1599587A2 (es)
JP (1) JP2007537984A (es)
KR (1) KR20050106483A (es)
AU (1) AU2004253846A1 (es)
BR (1) BRPI0408004A (es)
CA (1) CA2517684A1 (es)
MX (1) MXPA05009251A (es)
NO (1) NO20054336L (es)
RU (2) RU2005130636A (es)
WO (1) WO2005003164A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090298912A1 (en) * 2005-07-01 2009-12-03 The Johns Hopkins University Arginase II: A Target treatment of aging heart and heart failure
WO2007032717A1 (en) * 2005-08-03 2007-03-22 Astrazeneca Ab A method for identifying an agent that modulates arginine transport in a chondrocyte
JP2009511586A (ja) * 2005-10-11 2009-03-19 ワシントン・ユニバーシティ 気道分泌過多を治療するための組成物および方法
US20100056480A1 (en) * 2006-11-21 2010-03-04 Rijks Univesiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
WO2008091814A2 (en) * 2007-01-22 2008-07-31 Wyeth Assessment of asthma and allergen-dependent gene expression
ATE504296T1 (de) * 2007-03-06 2011-04-15 Rachid Ennamany Zusammensetzung auf basis von rutin und l-lysin
US8541183B2 (en) 2007-09-11 2013-09-24 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
ES2703714T3 (es) * 2009-03-12 2019-03-12 Cancer Prevention & Cure Ltd Métodos de identificación, evaluación, prevención y terapia de enfermedades pulmonares y kits de los mismos, incluida la identificación, evaluación, prevención y terapia de enfermedades en base al género
GB201007556D0 (en) * 2010-05-06 2010-06-23 Wetenschappelijk En Tech Ct Va Methods and compositions for textile layers and coatings
US8895528B2 (en) * 2010-05-26 2014-11-25 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
KR102008708B1 (ko) * 2010-06-23 2019-08-08 큐알엔에이, 인크. 전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료
EP3137103B1 (en) * 2014-04-29 2021-10-20 Bio-Cancer Treatment International Ltd. Methods and compositions for modulating the immune system with arginase i
CN110709936A (zh) 2017-04-04 2020-01-17 肺癌蛋白质组学有限责任公司 用于早期肺癌预后的基于血浆的蛋白质概况分析
CA3190519A1 (en) * 2020-08-26 2022-03-03 Cila Therapeutics Inc. Inhalable therapeutic agents

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4489710A (en) * 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
DE3280400D1 (de) * 1981-10-23 1992-06-04 Molecular Biosystems Inc Oligonukleotides heilmittel und dessen herstellungsverfahren.
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4625014A (en) * 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4638045A (en) * 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5266464A (en) * 1988-02-10 1993-11-30 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US4980281A (en) * 1988-02-10 1990-12-25 Housey Gerard M Method of screening for protein inhibitors and activators
US5688655A (en) * 1988-02-10 1997-11-18 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US5459039A (en) * 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US5866123A (en) * 1990-04-13 1999-02-02 Research Development Foundation Gene encoding cationic amino acid transporter protein
US6784163B1 (en) * 1990-04-13 2004-08-31 Macleod Carol L. Inhibition of cationic amino acid transporter protein and uses thereof
GB9509757D0 (en) * 1995-05-13 1995-07-05 Ilford Ltd Toning of photographic print material
WO2002015895A2 (en) * 2000-08-24 2002-02-28 The Regents Of The University Of California Alpha-difluoromethylornithine (dfmo) use in the human prostate
WO2003073990A2 (en) * 2002-03-01 2003-09-12 Children's Hospital Medical Center Treatment for asthma or allergies
AU2003218099A1 (en) * 2002-03-12 2003-09-29 Lsu Medical Center Modulation of the immune response through the manipulation of arginine levels
CA2515929C (en) * 2003-02-14 2013-11-19 Children's Hospital & Research Center At Oakland Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions

Also Published As

Publication number Publication date
US20040234517A1 (en) 2004-11-25
KR20050106483A (ko) 2005-11-09
JP2007537984A (ja) 2007-12-27
EP1599587A2 (en) 2005-11-30
NO20054336L (no) 2005-12-02
AU2004253846A1 (en) 2005-01-13
US20090156537A1 (en) 2009-06-18
RU2008145510A (ru) 2010-05-27
WO2005003164A9 (en) 2006-07-20
WO2005003164A2 (en) 2005-01-13
WO2005003164A3 (en) 2005-05-12
NO20054336D0 (no) 2005-09-20
CA2517684A1 (en) 2005-01-13
BRPI0408004A (pt) 2006-02-14
RU2005130636A (ru) 2006-05-10

Similar Documents

Publication Publication Date Title
MXPA05009251A (es) Composiciones y metodos para diagnosticar y tratar asma u otras enfermedades alergicas o inflamatorias.
Reeves et al. Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis
Cai et al. Angiotensin-(1–7) improves liver fibrosis by regulating the NLRP3 inflammasome via redox balance modulation
Jiang et al. Asymmetric dimethylarginine induces apoptosis via p38 MAPK/caspase-3-dependent signaling pathway in endothelial cells
SG151329A1 (en) Amido compounds and their use as pharmaceuticals
NZ588853A (en) Compositions and methods for treating and diagnosing asthma
WO2007090068A3 (en) Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
WO2008060813A3 (en) High affinity antibody antagonists of interleukin-13 receptor alpha 1
WO2008074997A8 (en) Pyridine benzamides and pyrazine benzamides used as pkd inhibitors
TW200626156A (en) Amido compounds and their use as pharmaceuticals
TN2009000137A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MX2009004475A (es) Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
WO2007038138A3 (en) Amido compounds and their use as pharmaceuticals
EA201201650A1 (ru) Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
NZ617196A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
NO20070372L (no) Amidoforbindelser og anvendelse derav som farmasoytiske preparater
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
WO2007082068A3 (en) Methods and compositions for treating asthma in human and non human primates
WO2008086043A3 (en) Methods and compositions for assessment and treatment of asthma
NZ596043A (en) Allergy inhibitor compositions and kits and methods of using the same
WO2007146730A3 (en) Deacetylase inhibitor therapy
BRPI0512379A (pt) composições farmacêuticas compreendendo inibidores de nep, inibidores do sistema de produção de endotelina endógena e antagonista do receptor at1
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
Rodríguez-Rojas et al. Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal